



**QUEEN'S
UNIVERSITY
BELFAST**

Single-cell multiomics reveals the complexity of TGF β signalling to chromatin in iPSC-derived kidney organoids

Davis, J. L., Kennedy, C., Clerkin, S., Treacy, N. J., Dodd, T., Moss, C., Murphy, A., Brazil, D. P., Cagney, G., Brougham, D. F., Murad, R., Finlay, D., Vuori, K., & Crean, J. (2022). Single-cell multiomics reveals the complexity of TGF β signalling to chromatin in iPSC-derived kidney organoids. *Communications Biology*, 5, Article 1301. <https://doi.org/10.1038/s42003-022-04264-1>

Published in:
Communications Biology

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

© 2022 The Authors.

This is an open access article published under a Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: <http://go.qub.ac.uk/oa-feedback>

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

Imaging data were collected using ZEISS ZEN 2012 (blue edition) (Zeiss Microscopy, Thornwood, NY) software installed on a ZEISS LSM800 confocal microscope or using LAS X software installed on a Leica SP8 confocal microscope. ChIP and Single cell RNA sequencing data were collected with the Illumina NextSeq control software installed on an Illumina NextSeq 500. Single cell ATAC sequencing data was collected with the Illumina NovaSeq control software installed on an Illumina NovaSeq 6000. Histological images were acquired using the EOS6000 Utility software (version:2.14.20a)

Data analysis

Fiji/ImageJ (version: 2.1.0/1.53q) was used for quantification of α SMA/DAPI and POSTN/DAPI areas, and quantification of picosirius red staining. Statistical analysis was performed in GraphPad Prism (version: 8.3.0). For scRNAseq data analysis: Cell Ranger (version: 3.1.0) was used to demultiplex, align, and generate single cell feature counts. scDblFinder was used to remove suspected doublets. Seurat (version: 3.0) was used for QC, normalisation, dimensional reduction, visualisation, clustering, and differential gene expression. Gene ontology was performed using Panther. Heat diffusion for affinity-based transition embedding (PHATE) was used to identify temporal cell trajectories and map cell fate lineages. Pseudotime trajectories were visualised using the using BBrowser software (version: 2.10). Protein-protein interaction networks were obtained using the public STRING database using Cytoscape (version 3.8.1). For scATACseq analysis: Cell Ranger ATAC (version: 1.2.0) was used to for demultiplexing and alignment. Signac(version: 1.1) was used to perform QC, generate gene activity matrix, visualization and clustering, motif analysis, differential accessibility analysis. Harmony was used for dataset integration. The Cicero package within Signac was used to construct and predict cis co-accessibility connections. Gene ontology was performed using Enrichr. SCENIC was used to determine potential regulatory transcription factors through the VSN nextflow pipeline (version: 0.26.1). For ChIPseq analysis: Illumina BaseSpace was used to align sequences to hg19 genome. Peak calling and data visualisation were performed on merged replicates using EaSeq (version: 1.111). Chromatin state segmentation was performed for iPSCs using ChromHMM from ENCODE on UCSC Genome Browser

(GRCH37/hg19). Chromatin state segmentation was performed for nephron progenitors using the 25-state chromatin model of the human foetal kidney (17 gestation weeks) epigenome (EID: E086; Donor/Sample ID: H-22676). Homer (version: 4.11) was used to perform comprehensive motif analysis. Potential enhancers were identified using human embryonic stem cell and fetal kidney data on Enhancer Atlas (version: 1.0) and GeneHancer (version 4.8). BigWig tracks for all samples were generated using usegalaxy.org. BigWig tracks were visualised using the UCSC Genome Browser.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

The datasets that support the findings of this study have been deposited at ArrayExpress with the accession codes: ChIP-seq data (Accession number: E-MTAB-10910), single-cell RNAseq data (Accession number: E-MTAB-11138) and single-cell ATAC-seq data (Accession number: E-MTAB-11139). Source data for ChIPseq graphs (Supplementary Fig. 1A and 1B), and statistical analysis of immunofluorescence and histological images (Fig. 3e, 3f, 4e, 4f and Supplementary Fig. 8b) are available in Supplementary Data 9. Source data for western blots are available in Supplementary Fig. 13. All R code used in this paper has been deposited on GitHub and is available at: https://github.com/CiaranKennedyUCD/Kidney_Organoid_Paper_scRNA_ATAC_seq (doi: 10.5281/zenodo.7311441).

Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender

Population characteristics

Recruitment

Ethics oversight

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size

Data exclusions

Replication

Randomization

Blinding

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input type="checkbox"/>	<input checked="" type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

Methods

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

Antibodies

Antibodies used

CDH1 (610181, mouse, monoclonal, BD Bioscience), Laminin (rabbit, polyclonal, L9393, Sigma), ZO-1 (rabbit, polyclonal, 61-7300, Invitrogen), MEIS1/2/3 (mouse, polyclonal, sc-101850, Santa Cruz), WT1 (mouse, polyclonal, sc-393498, Santa Cruz), SIX2 (11562-1-AP, Invitrogen), periostin (POSTN) (rabbit, polyclonal, PA534641, Invitrogen), PDGFRA (rabbit, polyclonal, PA516571, Invitrogen), PDGFRB (rabbit, monoclonal, 3169, Cell Signalling), and Alpha smooth muscle actin (α SMA) (A5228, Sigma)

Validation

Antibodies have been previously validated for immunofluorescence on frozen sections: CDH1 (Wang et al., 2021, PMID: 33643392), Laminin (Morizane et al., 2015, PMID: 26458176), ZO-1 (Vendor recommendation), MEIS1/2/3 (Geuens et al., 2021, PMID: 34198162), WT1 (Treacy et al., 2022 Bioactive materials, 2022, in Press MS No. BIOMAT1160), SIX2 (Morizane et al., 2015, PMID: 26458176), periostin (Vendor recommendation), PDGFRA (Agha et al., 2020, PMID: 32613166), PDGFRB (Roswall et al., 2018, PMID: 29529015; Treacy et al., 2022 Bioactive materials, 2022, in Press MS No. BIOMAT1160), alpha smooth muscle actin (Vendor recommendation; Kaji et al., 2020, PMID: 32501213)

Eukaryotic cell lines

Policy information about [cell lines and Sex and Gender in Research](#)

Cell line source(s)

The human iPSC line HPSI1213i-babk_2 purchased from the ECACC

Authentication

Cell line was authenticated by the ECACC (<https://ebisc.org/WTSli028-A>). iPSC line was routinely checked for pluripotency and genomic integrity by immunofluorescence of pluripotency markers and genetic analysis qPCR testing.

Mycoplasma contamination

Cells were mycoplasma tested once a month using the Lonza Mycoalert detection kit and all cells tested negative.

Commonly misidentified lines (See [ICLAC](#) register)

No commonly misidentified cell lines were used.

ChIP-seq

Data deposition

- Confirm that both raw and final processed data have been deposited in a public database such as [GEO](#).
- Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

<https://www.ebi.ac.uk/biostudies/arrayexpress/studies/E-MTAB-10910>

Files in database submission

IPSC_SMAD3_rep1, IPSC_SMAD3_rep2, IPSC_EZH2_rep1, IPSC_EZH2_rep2, IPSC_Input_1, IPSC_Input_2, D7_SMAD3_rep1, D7_SMAD3_rep2, D7_EZH2_rep1, D7_EZH2_rep2, D7_Input_1, D7_Input_2

Genome browser session (e.g. [UCSC](#))

No longer applicable

Methodology

Replicates

2 biological replicates were used for each condition

Sequencing depth

All samples were sequenced to a read depth of 25 million paired end reads

Antibodies	Smad3 (ab28379, Abcam) or EZH2 (5246, Cell Signalling)
Peak calling parameters	Peak calling was performed on merged replicates using EaSeq using the adaptive local thresholding method and default settings. Peaks overlapping blacklisted features as defined by the ENCODE project were removed.
Data quality	iPSC-SMAD3 - 971 peaks iPSC-EZH2 - 8528 peaks D7-SMAD3 2416 peaks D7-EZH2 1912 peaks
Software	Illumina BaseSpace, EaSeq, Homer, usegalaxy.org